ESR1 and breast carcinoma: Breast tumors are known to undergo genomic evolution, and ESR1 mutations (ESR1m) have been identified in 9–40% of patients with metastatic ER+ breast cancer resistant to aromatase inhibitors (AIs) (3–7).